Over the past two decades, the psychedelic ketamine has gained traction among scientists and mental health providers as a potential alternative treatment for depression. However, ketamine’s actions on a molecular level are still not fully understood, and its adverse side effects present a recurrent challenge. This review will provide an overview of results from preclinical and clinical trials of ketamine-based therapeutics for major depression

Psychedelic drugs are far from what is considered to be conventional medicine. An infamous history of misuse has stigmatized psychedelics, making it difficult to garner support for its use as a potential therapeutic tool. However, among working adults, taking low doses of psychedelics has recently gained popularity in its ability to boost productivity, reduce anxiety and depression ...